Align Technology, Inc. (ALGN) CEO Joe Hogan on Q2 2022 Results - Earnings Call Transcript
Align Technology, Inc. (NASDAQ:ALGN) Q2 2022 Earnings Conference Call July 27, 2022 4:30 PM ET
Company Participants
Shirley Stacy - Vice President-Corporate Communications & Investor Relations
Joe Hogan - President & Chief Executive Officer
John Morici - Chief Financial Officer
Conference Call Participants
Nathan Rich - Goldman Sachs
Elizabeth Anderson - Evercore
Jon Block - Stifel
Jeff Johnson - Baird
Jason Bednar - Piper Sandler
Erin Wright - Morgan Stanley
Brandon Couillard - Jefferies
Kevin Caliendo - UBS
Michael Ryskin - Bank of America
Operator
Greetings. Welcome to the Align Q2 2022 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please note this conference will be recorded.
I will now turn the conference over to your host, Shirley Stacy with Align Technology. You may begin
Shirley Stacy
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today’s call is Joe Hogan, President and CEO; and John Morici, CFO.
We issued second quarter 2022 financial results today via Business Wire, which is available on our website at investor.aligntech.com. Today’s conference call is being audio webcast and will be archived on our website for approximately one month. A telephone replay will be available today by approximately 5:30 PM Eastern Time through 5:30 PM Eastern Time on August 10. To access the telephone replay, domestic callers should dial 866-813-9403 with access code 137829. International callers should dial 929-458-6194 using the same access code.
As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align’s future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly and Align expressly assumes no obligation to update any forward-looking statement.
We have posted historical financial statements, including the corresponding reconciliations, including our GAAP to non-GAAP reconciliation, if applicable, and our second quarter 2022 conference call slides on our website under quarterly results. Please refer to these files for more detailed information.
And with that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
Joe Hogan
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide an overview of our Q2 results and discuss the performance of our two operating segments, Systems and Services and Clear Aligners. John will provide more detail on our financial performance and our view for the remainder of the year. Following that, I'll come back and summarize a few key points and open the call to questions.
I'm pleased to report solid second quarter results with top line revenues relatively unchanged from Q1, and operating margin of approximately 20%, despite unfavorable foreign exchange. The underlying market for orthodontics continues to be impacted by macroeconomic environment factors and lingering effects of COVID-19 variants in certain markets. Notwithstanding, these headwinds, we've remained focused on achieving our strategic initiatives, including opening new offices in the Middle East and Africa and our new manufacturing facility in Poland, launching new solutions to better support the way our customers want to do business, such as a doctor subscription program, and teen case packs, and announcing new products and innovation to help our doctors and their patients.
These new innovations are revolutionizing the digital treatment planning and helping to drive the evolution of digital orthodontics and comprehensive dentistry. Align is well-positioned to withstand the current market conditions to lead the digital revolution in orthodontics and dentistry as the environment and growth trends improve.
For System and Services, Q2 revenues were up 4.7% sequentially and up slightly year-over-year compared to Q2 2021 year-over-year growth of 215%. Q2 Services and Systems revenues increased sequentially driven by scanner volume growth in the Americas and APAC, partially offset by lower volume in EMEA, and unfavorable impact of foreign exchange.
The iTero Element 5D imaging system continues to represent the majority of our scanner volume as doctors recognize the benefits of going digital.
In APAC, the iTero entry-level Flex scanner offering was up sequentially in Q2, reflecting increased adoption. I'm also pleased with sequentially increasing services revenues in Q2, reflecting growth from the installed base. Services revenues represent approximately 40% of our Systems and Services business.
For our Clear Aligner segment, Q2 revenues were down slightly sequentially and down 5.1% year-over-year compared to our Q2 2021 record year-over-year revenue growth of 182%. For the quarter, Q2 Clear Aligner volumes reflect sequential growth across the Americas and parts of EMEA, partially offset by China and UK
Q2 Invisalign case starts for teens and younger patients was 177.3000 up slightly sequentially and down 2.1% year-over-year compared last year when our Teen case shipment growth rate was an all-time high. For Q2, Invisalign First for kids as young as six years old, grew year-over-year and was strong across all regions.
During Q2, we introduced Invisalign Teen Packs in the US and Canada and France. Teen Packs, our new subscription program, which enables orthodontists to buy clear aligners and packs in advance, similar to the way they buy wires and brackets today. Our Teen Case Pack simplified the ordering process and make the billing more predictable for doctors.
Teen Case Packs also include exclusive practice development benefits with the Invisalign brand and requires an incremental volume commitment from doctors. To date, enrollment has been encouraging with early adoptions highest among doctors who have not historically used Invisalign aligners to treat their teen patients.
For other non-case revenues, which include retention products such as Vivera Retainers, clinical training and education, accessories, e-commerce and our new subscription programs such as our DSP revenues, were up both sequentially and year-over-year.
For retainers, Q2 shipments had strong momentum with sequential and year-over-year growth across all regions driven by both submitters and utilization. Momentum in our doctor subscription program continued and Q2 revenues increased over 60% sequentially. Now let's turn to the specifics around our second quarter results, starting with the Americas.
For the Americas region, Q2 Invisalign case volumes were up sequentially, reflecting increased submissions from the orthodontic channel and increased utilization from the GP channel. From a product standpoint, Q2 sequential Invisalign case growth reflects increases in both comprehensive and non-comprehensive products, including Invisalign First and Invisalign Moderate.
Q2 also benefited from increased utilization in the DSO channel. Our international Clear Aligners, Q2 Invisalign case volumes were down 1.7% sequentially, primarily as a result of the headwinds described previously.
For EMEA, Q2 Invisalign case volumes were down slightly primarily reflecting a slight increase in Iberia and Italy, offset primarily by slightly lower sequential volumes in the UK and France. For Q2, expansion market shipments declined sequentially. Q2 Invisalign teen patients increased sequentially driven by an increase in the number of doctors submitting teen cases.
Turning to APAC. Invisalign case volumes were down slightly, reflecting a full quarter effect of continued lockdowns in China. For Q2, Taiwan, Hong Kong, Japan and India performed well during the quarter. On a year-over-year basis, Invisalign case shipments growth was strong in Japan, India, Taiwan, Thailand and Korea. The APAC teen case volume increased year-over-year, primarily driven by increased doctor submitters.
Turning to new innovations. The Align Digital Platform is an integrated suite of proprietary technologies and services delivered as a seamless end-to-end solution to customers that connects all users, doctors, labs patients and consumers to transform smiles, and change lives. Our technology advancements help our doctor customers deliver superior clinical outcomes, treatment efficiency and also superior patient experience.
In Q2, we introduced Invisalign Outcome Simulator Pro and Cone Beam being Computed Tomography systems, integration for ClinCheck software, building on several new innovations announced last quarter that we'll begin rolling out across the regions in August.
Invisalign Outcome Simulator Pro, the next-generation patient communication tool that empowers doctors to help patients visualize their potential new smile after Invisalign treatment. Use in-phase visualization in 3D dentition view, all done chairside in minutes. Cone Beam Computed Tomography systems, or what we call CBCT, integration for ClinCheck software is designed to deliver a complete view of a patient's roots, crown and jawbone. CBCT integration for ClinCheck software enables doctors to confidently deliver a more informed Invisalign clear liner treatment plan or a wide range of cases.
The user-friendly interface makes easy for doctors to see their patients root, crown and jawbone and one automatically digitally fused 3D model. This allows doctors to tailor their treatment plan based on their experience and their patients' needs. CBCT integration for ClinCheck software gives doctors the control and confidence to expand treatment planning to a broad range of mal inclusions, including surgical, restorative, expansion, extraction as well as teen cases with impacted or unterrupted team.
While it's still early in the commercialization of these new products, initial feedback from doctors is encouraging. We are excited to begin scaling them across our customer base in the second half of 2022. Also, during the quarter, we awarded 11 new research grants, totaling $275,000 to universities around the world. Through our annual research awards program, we help advance orthodontic and dental research, furthering our commitment to the future of digital orthodontics and restorative dentistry.
Our consumer marketing is focused on educating consumers about the Invisalign system, and driving that demand to Invisalign doctors offices, ultimately capitalizing on the massive market opportunity to transform 500 million smiles. For Q2, we had over 16.2 million visits to our websites, a 15% year-over-year increase, and delivered over 6.3 billion impressions. Both metrics were lower versus Q1 as we chose to rightsize our size and media spend in Q2, given the macroeconomic environment.
During the quarter, we built on our successful “Invis Is” multimedia campaign and launched in the US the next evolution with two new campaigns, “Invis Is” trauma-free, targeted at teens, and Invis Is when everything clicks, targeted at adults. Our Invis Is trauma-free campaign highlights the benefits of Invisalign treatment, while numerously juxtaposing teams with the significant hassles involved with using braces.
Our Invis Is when everything clicks campaign showcases Invisalign treatment, transforming smiles and the resulting confidence it gives the young adults. Both campaigns will be rolled out to markets around the world in Q3.
About some of our consumer patient app My Invisalign continued to increase with 1.8 million downloads to date. Uses of our four digital tools continues to increase, for example, Invisalign virtual appointment tool was used over 12,000 times, and our insurance verification feature was used 36,000 times in Q2. Further, we received more than 91,000 patient photos in our virtual care feature globally, which continues to provide us with rich data to leverage our artificial intelligence capabilities and improve our services for doctors and patients. Additional consumer demand metrics are included in our Q2 earnings slides posted on our website.
We are pleased with our Q2 Systems and Services revenues, which were up 5% sequentially and up 1% year-over-year. Q2 sequential growth primarily reflects higher scanner volumes in the Americas and APAC, and increased subscriptions. Year-over-year results primarily reflect increased scanner revenues in the Americas, offset by lower volume in APAC and EMEA.
Growth of our iTero scanner installed base is driving an increase in services revenue. On a year-over-year basis, Systems and Services growth reflects increased service revenues from our largest scanner installed base, higher subscription revenues and increased sales of scanner once leased.
The number of intraoral digital scans used for Invisalign case submissions in Q2 reflect continued adoption of our digital scanners and our larger installed base. Total worldwide intraoral digital scan submitted to start an Invisalign case in Q2 increased 88.4% from 82.2% in Q2 of last year. International intraoral digital scans for Invisalign case submissions increased 84.4%, up from 76.2% in Q2 of last year. For the Americas, 91.4% of Invisalign cases were submitted using an intraoral digital scan compared to 87% in Q2 last year. Cumulatively, over 60.4 million orthodontic scans and over 12.6 million restorative scans have been performed with iTero scanners.
Our Q2 exocad CAD/CAM products and services, which include restorative dentistry, implantology, guided surgery and smile design offerings are included in our Systems and Services revenue. Exocad products and services are helping extend our digital dental solutions and broaden the Align Digital Platform towards fully integrated interdisciplinary end-to-end workflows.
During the quarter, exocad released dental CAD 3.1 Rijeka in the new powerful lab software, which saves design time and offers more intuitive workflows along the designs earning from CAD to CAM. In addition, the release -- the exocad release launched the new, myexocad portal, introducing mandatory end-user software use registration that for the first time, allows exocad to collect information about who and how customers are using the software. This expands the opportunities for future product improvements. Also during the quarter, we signed a new long-term contract with exocad’s largest customer, Arming Gearbox, further strengthening our relationship.
Finally, we continue to execute our strategy of geographic expansion. In June, our European manufacturing facility in Wroclaw, Poland began manufacturing clear aligners for the EMEA region. Locally, for the first time, we also continued our operational expansion in Poland with our latest treatment planning facility. Our expanded operation in Poland supports Invisalign doctors in local languages, increases our flexibility and timeliness and supporting our doctor customers across the region, and we expect will positively influence the quality and time of preparation of ClinCheck treatment plans and provide our doctor customers with benefits of digital orthodontics with the Invisalign system. We are uniquely positioned with manufacturing and treatment planning in all three regions, and no other clear aligner manufacturer has our global footprint and capabilities.
With that, I'll now turn the call over to John.
John Morici
Thanks, Joe. Now for our Q2 financial results. Total revenues for the second quarter were $969.6 million, down 0.4% from the prior quarter and down 4.1% from the corresponding quarter a year ago. This is compared to Q2 2021 revenues of $1 billion, which had a year-over-year growth rate of 186.9%.
For clear aligners, Q2 revenues of $798.4 million were down 1.4% sequentially, due primarily to product mix and unfavorable foreign exchange, partially offset by higher non-case revenues, and down 5.1% year-over-year, primarily reflecting lower volumes, unfavorable impact from foreign exchange and product mix shift, partially offset by higher additional aligners per order processing fees and higher non-case revenues.
Q2 2022 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $12.3 million, or approximately 1.5% sequentially, and approximately $32.9 million, or approximately 4% year-over-year. For Q2, Invisalign comprehensive ASPs decreased sequentially and increased year-over-year. On a sequential basis, the decline in comprehensive ASPs reflect higher discounts and unfavorable impact from foreign exchange, partially offset by higher additional aligners. On a year-over-year basis, higher comprehensive ASPs reflect the impact of higher additional aligners and per order processing fees, partially offset by the impact of unfavorable foreign exchange and higher discounts.
Q2 Invisalign non-comprehensive ASPs increased sequentially and year-over-year. On a sequential basis, Invisalign non-comprehensive ASPs were favorably impacted by lower discounts, partially offset by product mix and unfavorable foreign exchange. On a year-over-year basis, higher Invisalign non-comprehensive ASPs reflect lower discounts, per order processing fees and higher additional aligners, partially offset by the impact of unfavorable foreign exchange and product mix shift.
Clear Aligner of deferred revenues on the balance sheet increased $25.4 million, or 2.3% sequentially and $231 million, or up 2.5% year-over-year, and will be recognized as the additional aligners are shipped. Q2 2022 Systems and Services revenue of $171.2 million were up 4.7% sequentially, primarily due to higher scanner volume and ASP, and were up slightly by 0.8% year-over-year, primarily from higher services revenues from our larger installed base, partially offset by lower scanner volume and lower ASP.
Systems and Services revenue were unfavorably impacted by foreign exchange of approximately $2.9 million, or approximately 1.7% sequentially. On a year-over-year basis, Systems and Services revenue were unfavorably impacted by foreign exchange of approximately $7 million, or approximately 3.9%.
Systems and Services deferred revenues on the balance sheet was $13.3 million, or 5.4% sequentially, and up $99.6 million, or 62.3% year-over-year primarily due to the increase in scanner sales and the deferral of service revenues included with the scanner purchase, which will be recognized ratably over the service period.
Moving on to gross margin. Second quarter overall gross margin was 70.9%, down two points sequentially and down 4.1 points year-over-year. Overall, gross margin was unfavorably impacted by approximately 0.5 points sequentially and 1.1 points on a year-over-year basis due to foreign exchange.
Clear Aligner gross margin for the second quarter was 73.3%, down 1.5 points sequentially due to lower ASPs and higher freight costs. Clear Aligner gross margin was down 3.6 points year-over-year due to a higher mix of additional aligner volume, higher freight and manufacturing spend, partially offset by higher ASPs.
Systems and Services gross margin for the second quarter was 59.8%, down 3.6 points sequentially due to higher manufacturing variances and freight costs, partially offset by higher ASPs. Systems and Services gross margin was down 6.1 points year-over-year due to lower ASPs and higher manufacturing variances, partially offset by higher service mix.
Q2 operating expenses were $499.4 million, down sequentially 2.3%, and up 2% year-over-year. On a sequential basis, operating expenses were down by $11.9 million mainly due to lower incentive compensation and controlled spend on advertising and marketing as part of our efforts to proactively manage costs.
Year-over-year, operating expenses increased by $9.7 million, reflecting our continued investment in marketing, sales and R&D activities and investments commensurate with business growth.
On a non-GAAP basis, excluding stock-based compensation, amortization of acquired intangibles related to certain acquisitions and acquisition costs, operating expenses were $466 million down sequentially 3% and up 1% year-over-year.
Our second quarter operating income of $188.2 million resulted in an operating margin of 19.4% and down 0.9 points sequentially and down 7.2 points year-over-year. Operating margin was unfavorably impacted by approximately 1.1 points sequentially due to foreign exchange.
The year-over-year decrease in operating margin is primarily attributable to lower gross margin, investments in our go-to-market teams and technology as well as unfavorable impact from foreign exchange by approximately 2.4 points.
On a non-GAAP basis, which excludes stock-based compensation, of intangibles related to certain acquisitions and acquisition costs, operating margin for the second quarter was 23.3%, down 0.7 points sequentially and down 6.5 points year-over-year.
Interest and other income expense net for the second quarter was a loss of $14.6 million, down sequentially by $4 million and down year-over-year by $14.5 million, primarily due to larger net foreign exchange losses from the weakening of certain foreign currencies against the US dollar.
The GAAP effective tax rate in the second quarter was 35% compared to 28.4% in the first quarter and 25.7% in the second quarter of the prior year. Our non-GAAP effective tax rate was 25.6% in the second quarter compared to 24.2% in the first quarter and 19.5% in the second quarter of the prior year.
The second quarter GAAP effective tax rate was higher than the first quarter effective tax rate primarily due to foreign income tax at different rates and lower excess tax benefits from stock-based compensation.
Second quarter net income per diluted share was $1.44, down sequentially $0.26 and down $1.07 compared to the prior year. Our EPS was unfavorably impacted by $0.26 on a sequential basis and $0.42 on a year-over-year basis due to foreign exchange. On a non-GAAP basis, net income per share was $2 for the second quarter, down $0.13 sequentially and down $1.04 year-over-year.
Moving on to the balance sheet. As of June 30, 2022, cash, cash equivalents and short- and long-term marketable securities were $977.2 million, down sequentially $143.4 million and down $109.2 million year-over-year. Of our $977.2 million balance, $251.4 million was held in the US and $725.8 million was held by our international entities. Q2 accounts receivable balance was $931.9 million, down approximately 2% sequentially. Our overall days sales outstanding was 85 days, down approximately two days sequentially and up approximately 13 days as compared to Q2 last year.
Cash flow from operations for the second quarter was $127 million. Capital expenditures for the second quarter were $76 million, primarily related to our continued investments to increase aligner manufacturing capacity and facilities. Free cash flow, defined as cash flow from operations less capital expenditures amounted to $51 million.
In Q2, we purchased $200 million of our common stock through an accelerated stock repurchase program, receiving approximately 757,000 shares at an average price of $264.37 per share. We are over halfway through our May 2021 $1 billion repurchase program, and have approximately $450 million remaining available for purchase.
Now turning to full year 2022 and the factors that influence our views on our business outlook. Overall, our Q2 results were solid, and we feel good about the execution across the business, especially in an increasingly challenging global economic environment. Delivering revenues and volumes relatively unchanged from Q1 and down only slightly year-over-year despite unfavorable impacts from foreign exchange speak to the strength of our underlying products and services and the size of our market opportunity.
We remain confident in the huge underpenetrated market for digital orthodontics and restorative dentistry, our technology and our industry leadership and our ability to execute and make progress towards our long-term model of 20% to 30% revenue growth. We also remain committed to our goal for fiscal 2022 to deliver GAAP operating margins above 20%, while making strategic investments in sales, marketing, R&D and operations, notwithstanding the impact from unfavorable foreign exchange, which was not factored into our operating margin guidance for the full year.
Capital expenditures primarily relate to building construction and improvements as well as a digital manufacturing capacity to support our international expansion. For 2022, we expect our investment in capital expenditures to exceed $300 million. This includes our investment in our aligner fabrication facility in Wroclaw, Poland.
In times like these, our strong fundamental Business differentiates align, and we are grateful to have a profitable underlying business model that generates strong cash flow as well as a healthy balance sheet that provides flexibility to invest in our growth while supporting our employees, customers and shareholders. As we move into the second half of the year, we will continue to manage our investments to account for headwinds and uncertainty while focusing on successfully delivering on our strategic growth drivers.
With that, I'll turn it back over to Joe for final comments. Joe?
Joe Hogan
Thanks, John. Closing Q2 in the first half of 2022 has proved to be tougher than we expected. As we continue to navigate macroeconomic uncertainty and weaker consumer confidence and impacts related to COVID-19 variance, we cannot lose sight of the strong fundamentals of our business and the enormous market opportunity for digital orthodontics and restorative dentistry.
The decisions we make this year will have lasting strategic implications for the future of our industry and the competitive landscape. We are holding true to our business strategy, and making good progress in a very difficult operating environment. We remain committed to balancing investments to drive growth and long-term strategic priorities with near-term headwinds while acting with a sense of urgency to ensure that we're ready to capitalize and extend our global innovation leadership as growth resumes.
Thanks for your time today. We look forward to updating you on our next earnings call. With that, I'll turn it over to the operator. Operator?
Question-and-Answer Session
Operator
Thank you. At this time, we will conducting a question-and-answer session. [Operator Instructions] The first question is from Nathan Rich with Goldman Sachs. Please proceed.
Nathan Rich
Thank you, good afternoon. Hey, Joe and John. I guess, I wanted to start high level. Joe, you kind of highlighted the consistent case in revenue trends in the second quarter relative to the first. But within the context of a challenging macro environment, I guess, how does that influence your thinking on the trajectory of the business? And have you seen an impact on patient traffic to dental practices or treatment acceptance rates that's kind of driving that commentary?
Joe Hogan
Nate, it's a -- if you look at this from a domestic standpoint, you can pull out some signal, but I think you have to when you're asking a demand question like that, you have to look at this globally. And I think like John and I were just clear in our introduction that basically, if you took Asia, COVID-19 impacted us pretty tremendously in Asia. Japan for a little bit in the first part of the quarter in China almost throughout the quarter. So it was really a COVID discussion there, and it's hard to pull a demand signal out.
In the United States, I mean, if you look at the data that we do, you'll see from a general practitioner standpoint or whatever, some stability in patient vision to what's going on. Our concern here is, obviously, this is a product where like a cap or a crown or cleaning or something that needs to be done, it's somewhat discretionary. And we see that from an adult standpoint, more variability in adult selection than in teens. Teens have been pretty stable in that way if we talked about before.
Moving over to Europe. We're working off 300% growth rates in Europe last year, okay, which you have to internalize that. It's a pretty big comparison year-on-year. And there weren't standard vacations being taken in Europe to the beginning of the end of the second quarter and the third quarter.
So overall, I'd say, as you look around the globe, I fee like -- I felt good, as we mentioned in the script, about Q1 versus Q2 and pretty much the same kind of demand pattern. But right now, I can't really give you a trajectory in the third quarter and the fourth quarter, because of the macro environment, concerns again in China from another COVID shutdown and those types of things. I hope that makes sense, Nate.
Nathan Rich
Yes, definitely. And maybe just a quick follow-up. – were you, I guess, able to size kind of the headwind from the lockdowns in China? And with that -- in that market specifically, have you started to see those volumes recover as we're starting to see those lockdowns ease?
Joe Hogan
For sure. I mean it's direct correlation there as soon as they let Shanghai open again, we saw it reflected in our order rates there. And look, we continue to feel good about China in a stable market. It's just the dramatic way that China continues to address COVID cases by major cities. This just creates a huge amount of uncertainty as when the next lockdown will be.
Nathan Rich
Thank you.
Joe Hogan
Thank you.
Operator
Thank you, Mr. Rich. The next question is from the line of Elizabeth Anderson with Evercore. Please proceed.
Elizabeth Anderson
Hi, guys.
Joe Hogan
Hi, Elizabeth.
Elizabeth Anderson
Thanks so much for the question. One thing I was wondering if you could comment about -- I know in the sort of fourth quarter of last year, and into the first quarter, you did increase the sales hiring, sequentially and year-over-year. Could you sort of talk through sort of the impact of those salespeople? Where are they in the ramp process? And how do you -- should we think about their potential for contributing in the back half of the year? Thanks.
Joe Hogan
That's a good question, Elizabeth. Obviously, our sales force -- being a direct sales force is really important to us in that way. And so the way we do this, obviously, as you indicated, we hire a lot of salespeople upfront. We have sales training programs too that help to initiate them as they come into the corporation. But I would tell you, depending on where you are around the globe, there is a six-month and nine-month burn-in period, before you really feel that they're up to speed. They understand the Invisalign system, the digital platform and those types of things. So I would say in some simpler kinds of situations geographically, it could be six months. But in general, it's nine months or so before we have confidence that they're going to be really good on their feet as they talk to our doctors.
Elizabeth Anderson
Got it. That's helpful. And then one thing that depressed me in the quarter a little bit was about the teen number. I know that sometimes this quarter, it's been off because of COVID in terms of seasonality, and it's not necessarily always the strongest quarter for teen. But how are you thinking about that versus the economic sensitivity of adult cases and sort of how -- do you expect that to sort of trend in the sort of near-term?
Joe Hogan
Yes. Keep in mind, we see a lot more concern from an adult standpoint, when you look year-over-year in the sense of our order growth in adults, I mean it's been affected Elizabeth, and there's a lot of data that we produce that will show you that.
On the teen side, it's hard to pull a lot of the second quarter because it really starts in the third quarter. But I felt overall good about it, but again, not surprised because we've always felt that teens have a certain window of time from a treatment standpoint. And so it's not necessarily an emotional purchase in a way, it's usually planned for and anticipated. And -- and what we saw between the second quarter and beginning of the third quarter, it really bears that out.
Elizabeth Anderson
Got it. Okay. Thank you very much.
Joe Hogan
You’re welcome.
Operator
Thank you, Ms. Anderson. Our next question is from the line of Jon Block with Stifel. Please proceed.
Jon Block
Great. Thanks, guys. Good afternoon. I'll follow up on teen, maybe just to go there. I think worldwide teen was down year-over-year. And I believe, Joe, you mentioned that teen and APAC was up year-over-year, which sort of implies that North American teen was down maybe a decent amount. So anything to call out there? Why do we see that maybe specific to North America? And then more importantly, you did have some positive commentary around teen case packs, you talked about enrollment. So maybe just talk to us on how long it might take for the teen case pack program in North America to give that segment a shot in the arm and then your plans to roll that out internationally? I've got a follow-up.
Joe Hogan
Jon, on the teen side, remember, we kind of lost -- or we had a muted signal on the team side. It needs to be very clear from quarter-to-quarter before COVID. If you remember last year, it was much more muted. This year, we're hoping to see a less muted cycle. And I think we're starting to feel that, Jon. So it's -- I don't think you can look too much between what we're doing between the first quarter and second quarter and pull a clear teen signal out of there.
The other thing on teen too is there's always competitive concern with other clear aligner whatever. But basically, this is a wires and brackets competition with us. It's always been and continues to be that way. And in new products that we're launching these teen packs, we feel good about them. They've been -- as I mentioned in my script too, they've been received well. And it's been with the lower-end orthodontics from our standpoint that haven't done a lot of teen cases in the past. And that's a segment that we were fishing for to give them more confidence to be able to move in with teens.
So we're not declaring victory, but we feel we have a good product that's timed well. And we're not seeing the cycles in the teen marketplace as we're seeing in the adult marketplace. And obviously, Jon, as we get through the third quarter, we'll have a much better understanding of how we turn out that way. But I didn't pull anything out between the first and the second quarter that concerned me.
Jon Block
Got it. Helpful. Thank you. And then for my second one, let me try to maybe jam two in one, and hopefully not make a mess of it. So just for us on the 3Q versus 2Q overall case volumes, China is reopened. China is a decent chunk of business for you guys. So if China snaps back, you talked about Shanghai, then maybe talk to us on why we wouldn't see you guys resume some sequential growth 3Q versus 2Q? I know there's many other markets.
And then maybe just to stick with China. I just love your thoughts on what's going on over there, maybe in terms of market share, your main competitor had some quasi numbers out recently. It looked like they were down mid-single digits in cases 1H 2022 year-over-year, which quite honestly, I actually thought that was a good number considering the environment. So I would love your thoughts on just China and your ability to hold share on what's going on from a market share perspective? Thanks guys.
Joe Hogan
Yeah. I'll start with the China and move backwards, Jon. And I'll get John involved here, too. But from the China side, obviously, we saw what you published there, whatever, but I looked at Angel numbers, and it basically same thing we experienced. I mean, we experienced a shutdown of Shanghai, slowdowns in some other regions, and there was nothing in those numbers that really surprised me.
As I look at China, our ability to compete there. I feel great about it. And again, our investments we've made there in treatment planning and manufacturing. We've only added to that. The efficiency of those organizations have done well. Our product is great for that marketplace, and some of the most difficult cases that we encounter exist there, too.
So I feel good about our ability to compete in that market against Angel or anyone else who's there. We just need a stable marketplace that we can operate in, and it hasn't been stable for -- goodness knows, it's been, what, almost two years. And I mean I just read this morning, the Wuhan's looking at the close down.
So I mean, Jon, there's a lot of variability there, a concern with COVID and shutdowns, particularly in the second half of this year in China, but I continue to be concerned about that can disrupt the marketplace. But if that stays clear, we're going to have China in the second half that we can operate from. To answer your question, I feel good about our competitive position there, our ability to compete against with anyone.
John Morici
And we should see some of the sequential history that we normally see in our business. It goes to what Joe said that, there's just some unforeseen variables that are still there. If there is a shutdown in China, that will impact our numbers. If there's no shutdown, we should see sequential improvement. And then you have some of the other macro economics that we've talked about in terms of potential recession or other things that people are concerned about, that affects their decisions on whether they go into treatment. But we're watching closer to see how sequentially things are behaving and making investments appropriate based on what we see.
Joe Hogan
And Jon, sorry, just staying back to your second question...
Jon Block
Sorry. if I can just jump in...
Joe Hogan
Go ahead, Jon.
Jon Block
Sorry, Joe. I was just going to say, John and Joe, maybe to follow up on that lasts comment just for clarity purposes because I think it's an important one. Are you guys saying sort of as you sit here today, who the heck knows what's going on with Wuhan, I don't know, something worse incrementally with the economy. But as we sit here today in late July, you're expecting the resumption of sequential growth off the 2Q number, this evening?
Joe Hogan
Well, I'd say, Jon, expecting anything in this market might be a sign of a low IQ. When you look at what's going on in China, I'm not going to sit here and tell you I expect a stable market in the second half based on their COVID policies. So I hope -- from the United States standpoint, there's a lot going on trying to explain to the teen market overall outside of China, I feel is the most stable market we have, and the one that we're ready to compete with, and we're moving into seasonality, what really makes a difference.
We have -- we're positioned well with products. But as you know, Jon, as well as anybody, that's always been a wires and brackets marketplace. We've been taking share 1.5 points, two points a year. We're hoping some moves we make can make that better, but we'll know a lot more when the third quarter is over in the sense.
Jon Block
Okay. Very helpful. Thanks, guys.
Joe Hogan
Thanks, Jon.
Operator
Thank you, Mr. Block. Our next question comes from the line of Jeff Johnson with Baird. Please proceed.
Jeff Johnson
Thank you. Good afternoon, guys. Joe – hey, Joe, so I just wanted to talk maybe on the doctor shift to that number this quarter. It's trended down each of the last couple of quarters. This quarter in the Americas, it did trend back up just a touch. What are your views on what that means? Is that a -- market stabilized a little bit? Is that maybe the competitive positioning is stabilizing a little bit? Just how do you view that number in the Americas? And is there room left in the Americas for that number over the next couple of years to keep moving higher? Are you kind of at a point where you've saturated kind of the Americas market with a number of doctors who are going to be performing in these cases?
Joe Hogan
Just to answer your last part of your question first, Jeff. No, we have a lot of room to grow in the Americas, too. In United States, Canada, but also you have to throw in Latin America and Brazil in that. There's a lot of growth, John and I have ported over these numbers a lot.
You know what happens, if you backed these numbers up before really the big surge in orders that we had before, we can draw a line through these things. It doesn't upset us. You have to split orthos and GPs very clearly. Remember, you have some GPs that do like three cases a year. As things kind of slow down, they'll be out of the circulation for a while and then they order another and whatever. And these numbers will go up 81, 1,000, 2,000, we'll see them go up and down. But don't look at this in any way as that we're saturated in this marketplace, both from an orthodontic standpoint and a GP standpoint.
Jeff, the other thing too, I think, that people forget from an orthodontic standpoint is that our orthodontists who do teens. These are orthodontists that are really committed to Invisalign for the most part, and they do a lot of teens. But we still have a significant amount of orthodontists at do Invisalign almost exclusively for adults. And so you'll see that whole piece from a utilization standpoint as we increase our team penetration, you should see the utilization rates there improve.
Jeff Johnson
Yeah, that's helpful. And then maybe kind of a follow-up on all that a two-parter, just the international number again, kind of, did tick down a little bit that number of factors shipped to internationally. One, I would assume you think there's a lot more room even there to saturate that market over the next few years, that would seem to make sense to me anyway. But is there any way to look at what that number did in China? And was there sequential decline largely driven by the shutdowns in China, or ex-China, would that number have been up?
And then I was a little surprised to hear cases down, I think you said in UK year-over-year. Is that just a tough comp, or what's going on in the UK? I think we are all aware of China pressures in early, Japan pressures or early quarter Japan pressures, but UK caught me off guard a little bit there? Thanks.
Joe Hogan
I'll answer the UK piece first. The UK was outstanding for us last year. Remember, Europe grew 300% for us last year, Jeff, right? The UK led that. So I'm sure that UK number is higher than what that aggregate number is. And so what you're seeing is adult retrenchment in the UK from an order standpoint, but not an indication of a utilization issue that I'd say, across the doctor base that we have in the UK.
John, I don't know…
Jeff Johnson
Thanks guys.
Joe Hogan
Yeah. Thanks Jeff.
Operator
Thank you, Mr. Johnson. Our next question is from the line of Justin Lin [ph] with William Blair. Please proceed.
Unidentified Analyst
Hi, good afternoon. Can you just touch on your sales and marketing spending strategy a little bit in the short-term and longer term? I guess, when can you decide to flip the switch?
Joe Hogan
You mean flip the switches as far as up or down?
Unidentified Analyst
Yeah, yeah.
Joe Hogan
Yeah. I mean, obviously, obviously, we saw our adults dramatically decreased, and so the return on investment in some specific geographies. John, as I take a look at it, and we don't eliminate it, but we reduce it in accordance with what we think the demand pattern is. And we spread it around into other countries that we feel we can get a higher return on. And we just basically sizing our advertising to what we think the demand patterns are around the business in different areas.
And so I wouldn't look at this as any way that we'll continue to advertise aggressively and promote our brand and to drive value in our change to bring customers to our doctor base, but we can be responsible to we can advertise at the rate that we did last year when we were growing at over 100% in a lot of these regions, we have to modify it somewhat in order to address that demand pattern.
John Morici
And we adjust into the market. So keep the overall brand awareness, keep that averages. Remember, still sudden spending even as we right-size things, hundreds of millions of dollars in marketing and media to be able to go to market, drive that awareness. But then in certain markets, if there's COVID or if there's economic concerns and so on, we're adjusting things to make sure that we right-size and continue to make sure that we make the right trade-off between how we're investing in go-to-market, and continue to reinvest in the rest of the business like R&D and operations.
Unidentified Analyst
Got it. That's very helpful. And I guess just pivoting to a more sort of higher-level question. Any update on commercial operations in sort of your emerging markets like Brazil, India, Africa, what would you say current penetration levels are over there? And I guess, realistically, how much revenue can you capture from those regions in the next, let's say, five to 10 years?
A – Joe Hogan
And the region that you mentioned were really underpenetrated, huge opportunity. I mean we've seen great progress in Brazil. We're seeing good progress in India. Reported in -- I mean, it's -- when we talk about those 500 million patients, they're out there. And the way to get them is we do -- we put salespeople in place. We put the right kind of capability on the ground.
This is a direct sales force that you have to have in order to sell our product line. But to answer your specific question, the penetration rates aren't even close. And that's -- again, you can see that in our script, that's how we remain so confident that in a stable environment, we'll continue to perform really well.
John Morici
And we're built as a company to really expand into those markets. We've got that global footprint for manufacturing now in all three geographies. We've got treatment planning. We've got that go-to-market sales force -- direct sales force with great products. So we're built in all those markets. We like the dynamics of these markets where you have a growing middle class, big population. You've got people who want to straighten their teeth, and we've got a great way for them to get to that. So all the markets you described as well as many others, those are where we think of some of the investments because it's a great return on those investments.
Unidentified Analyst
Got it. Thank you very much.
Joe Hogan
Thank you.
Operator
Thank you, Mr. [indiscernible]. Our next question is from the line of Jason Bednar with Piper Sandler. Please proceed.
Joe Hogan
Hi, Jason.
Jason Bednar
Hey, good afternoon. Yes. So Joe, I'll go big picture here in the US market, and maybe go back to clarifying point on Jon Block's question earlier. On one hand, demand in the category broadly just did seem to show some signs of moderation in the second half of last year relation to a bit of a leading indicator in other parts of high end then on the help of the average consumer. I mean this needs are going to be coming into some easier absolute comparisons as we head into the back half of this year, which I don't know, maybe helps reverse this downtrend in Invisalign case growth. But I guess we're also in the early days of what still could be some more pain coming for the consumer. So I guess what dominates in your opinion? Do the easier comps dominate, or does it more challenge on consumer dominate? And again, just thinking about the domestic market you're and ignoring again some of that China and predictability that's out there.
Joe Hogan
Yes. I'll let John take a shot at this, too. But I would say, I mean, obviously, you talk about easier comps. I mean when you're comping against 300% growth, like we just talked about, it's one of the tougher comps on a large number I've had in my business career. And so obviously, when you get some light on that line, it helps somewhat. But consumer confidence. I'd say, outside of the COVID, the way I'd look at the business again is COVID affected Asia in a big way. We had some COVID staffing issues or whatever, but predominantly in the West, it's consumer confidence that we look at.
And so those consumer confidence numbers start to equalize to start to get better. Some of the ones we look in Europe are all-time lows. I feel that means a lot. It means that means more to meet in those comparisons years from here. We report more confidence in consumers in a trend where in that kind of environment, we think we see the adult cases resume at a pace that we'd be equal to our long-term growth rate.
John Morici
Yes. It's consumer confidence overall, and in certain cases…
Jason Bednar
I guess, just real quick, I guess I would -- yeah, I guess I was just focusing more on the US market. And I totally understand Europe and China and APAC and all the different dynamics there. But just in within the US market, I mean, the comps do get easier, absolute comps -- they did tick down starting in the second half of last year. So just I'd be where I'd be focusing the question here, sorry to interrupt.
Joe Hogan
Yeah. No, Jason, that's okay. I look at the United States too is -- I just give you consumer confidence more than anything. Not just saying that there's no big variant issue or something that happens with COVID. We're all kind of have PTSD in that sense and what we experienced over the last two years.
But yeah, I like the comparison year-over-year. That's going to be helpful. But those consumer confidence numbers, whether I'm talking about Europe or I'm talking about the States, those are the ones that we stay alluded to that we think are a really good indicator in the sense of our market, and that adult market that we appeal to, both in the GP segment and the adult market in the orthodontic segment, too.
John Morici
And the piece that I would add to the US is just that as we get into teen season now as we go from Q2 to Q3. Teens will be important to see. We've got great products. We've got great go-to-market opportunities to be able to grow in those markets and get more market share. When we think of teens everywhere in the world, it's single digit and even in the US. So we look at growth opportunities that will be teens, maybe a little bit less of more resistant to maybe some of that consumer concerns that they have. Consumer concerns certainly show up on the adult side, but we think teams can help offset that just a bit because it's less discretionary.
Jason Bednar
Okay. That's helpful. And maybe just a quick follow-up here. A lot of questions out there right now from investors on the decremental margin impact for the business with volumes and revenue doing what it's doing here. You added a lot of head count. It's significantly expanded branding and advertising efforts during the pandemic really helped to widen the competitive moat, so really impressive. It sounds like some of that marketing though has been recalibrated here. Are there further resets that -- with the OpEx structure that might be necessary in this environment? And I guess, what's the trigger for you to decide that a further rightsizing is necessary?
Joe Hogan
I mean rightsizing, when I hear words like that, it means that we've gone to the layoffs, so we haven't laid anything off. Remember, we -- any one off in that sense. We normally hire to a 20% to 30% growth rate. And so -- and we -- our OpEx spend is in that range, too. So, obviously, we didn't -- we couldn't hire in that range, and so if you call that a cutback, it's a cutback from our normal OpEx.
What we do is we normally balance OpEx to revenue at about a 50% range, and there's a lot of variables in that line from an OpEx standpoint that we can go about. Remember, our most important areas that we want to make sure we take care of is our commercial team, our engineering effort and also our marketing. We know those are really key. And we focus on those, and we balance the business well.
John, anything you want to add?
John Morici
It's a balance, both short and long-term. So as we balance out our plans, we look to the growth opportunities we have, we want to make sure we continue to invest in those growth opportunities. But then obviously, we have to be mindful of the current conditions that we're in, and we'll adjust as needed to still maximize the return on investments that we're making.
Jason Bednar
All right. Thanks so much.
John Morici
Thanks Jason.
Operator
Thank you, Mr. Bednar. Our next question is from the line of Erin Wright with Morgan Stanley. Please proceed.
Erin Wright
Great. Thanks. And I wanted to ask another Americas teen question here. But just given the seasonality and given this is an area where you should have some better visibility. I just want to clarify, does this -- does this mean you're going to see a meaningful sequential pickup in the coming quarter, or why would that not happen for you? And just given that should be an area more under your control here. Thanks.
Joe Hogan
Yes. Our normal growth pattern between the second quarter and the third quarter is flat to down 1 percentage point or so. John can confirm that. So the second quarter to third quarter is a big teen season, but there's other parts of our portfolio that kind of balance out with that. It's not traditionally a jump from second to third quarter.
But again, we're focused on teens because we feel teens have a lot less elasticity than what adults have right now based on the consumer confidence level. So I just -- but I'd just caution you here. Remember, this is a wires and brackets play. It's something that's systemic that we have worked on for years. We have many new products like Invisalign First, I mean give advancement and several new teen products that help us with this. The new teen packs help also. We think we're well positioned, but we have to get into the quarter and be able to assess how well that market is actually holding up. John, anything...
John Morici
But specifically in the US, US teen, we should see sequential improvement as we get into teen season, going from Q2 to Q3, notwithstanding any occurrences that happened from an economic standpoint, but the expectation is given our products, given the opportunity, given the utilization that we have, we should be able to see growth. Notwithstanding, anything else that gets in our way.
Erin Wright
Okay. Thanks. And then ASPs for the balance of the year, how should we be thinking about that and the FX impact?
John Morici
Erin, FX, obviously, Q1 to Q2 was a big impact in FX. We see it in the numbers from revenue all the way down to our EPS. I would think of it's tough to forecast where FX is going to go. Certainly, dollar has strengthened. I think you kind of take the numbers that they're at now and kind of play that forward for the rest of the year is how we look at that.
I think from an overall ASP standpoint, there's always going to be puts and takes. So we're not doing anything different from a discounting standpoint, how we're going to market and so on. You might have some mix effects that come through. But I take the FX rates kind of as they are now, project those forward and then ASP should be too much different than what you see now notwithstanding any FX.
Erin Wright
Okay. Thank you.
Operator
Thank you, Ms. Wright. The next question is from the line of Brandon Couillard with Jefferies. Please proceed.
Brandon Couillard
Thanks, John, a quick follow-up on that FX question. I appreciate all the details in the deck. It is very, very helpful. Just curious, what is the estimated impact of currency on the operating margin for the year now in the ballpark?
John Morici
Well, ballpark, I would look at that is about 1 point, maybe just over 1 point of impact. We saw that 1.1 point impact from Q1 to Q2 in op margin. I would kind of look at the full year and about the same.
Brandon Couillard
Thanks. And then Joe, on the scanner business, any color between the North American segment and international in terms of growth rate, how would you sort of characterize the capital spending environment in those two regions, specifically?
Joe Hogan
Yes. I'll start with -- I mean, obviously, we had trouble selling scanners in China because China shut down. And China is one of our bigger markets is between China and Japan and Asia. So I didn't look at that so much as and overall market problem, I looked at that as more of a COVID problem. And so hopeful of, as I mentioned before, if that COVID stays clear, that will write itself.
United States, just a good job by the team, strong demand there. 5G plus tends to be the really strong scanner out there. On the restorative side, dentists liking the NERI, the near-infrared technology for carries detection and orthodontists continue like the exactness of how our workflows at all from an overall iTero standpoint. So I feel good about the Americas and what the performance was in that piece. And as I mentioned in my script is 40% with a large installed base now, 40% is services, too, which is really helpful in that business overall.
And look, I feel good about, again, our scanners in Europe compared to get some pretty big numbers again last year. So I wouldn't be blinded by the year-over-year number in that sense. But Europe has the added pressure right now from a Ukraine standpoint. It's just -- it wears on the consumer sentiment piece. I think it makes docs a little more reluctant in -- but there's -- I feel good about our position in Europe from a scanner standpoint. And as the market hopefully starts to stabilize here, we'll see that business that we had return loans.
Brandon Couillard
Okay. Thanks.
Operator
Thank you. Our next question is from the line of Kevin Caliendo with UBS. Please proceed.
Kevin Caliendo
Hi, thanks for getting me in. So just want to think about how -- or what it would take for you guys to feel comfortable with providing guidance again, or feeling comfortable that you can hit your longer term targets rather than making progress towards it. Do we need to see consumer confidence go back above 99% or something like that, or I mean, at the beginning of the year, you caveated and said, listen, if there's no more COVID outbreaks, we'd still be able to do this.
What do you need to see before you can come to us and say, hey, we're back on track or we think we can do this? So we feel comfortable. We're going to be able to grow at ex-rate going forward, even be able to provide guidance for like a quarter going forward, even if it's not for the full year. What needs to happen, in your mind?
Joe Hogan
I'll turn it over to John. But first of all is, remember, we don't carry inventory in this business outside of scanners. So it's a real-time business. We don't have any inventory to reflect from or any -- very little business from a week-to-week standpoint. So I'll move it over to John, but keep that in mind that we, kind of, feel these trends early on both ends. As the economy picks up, we'll probably feel it first. And as it turns down, we feel it by just the nature of the business first.
John Morici
It really comes down to, Kevin, more just having more predictability on a macro basis, understanding you mentioned COVID and thinking that we're through it, then you have China lockdowns or some of the consumer sentiment and things that come up that are outside of our control, we feel very good about being able to control what we can control, making the right investments as we go to market or adding investments in R&D to better our products and so on, and drive that return.
And, therefore, like I said, we can manage that 20%, that’s something that we can manage as we go through the quarter. It really comes out to having more predictability on a macro basis. And once we get confidence in that, and we work our way to that understanding, look, the economies are going to do what they're going to do. They're going to go up or down. But if I have more predictability on the direction that they're going and how they're going to go, then we can give a good forecast.
Kevin Caliendo
All right. Appreciate that. Thank you.
Operator
Thank you, Mr. Caliendo. Our next question is from the line of Michael Ryskin with Bank of America. Please proceed.
Michael Ryskin
Great. Thanks for taking the question guys. I have kind of a follow-up to one of the earlier ones, and some that Kevin just asked sort of on the moving pieces going forward. I mean we spent a lot of time talking about China lockdowns and the impact that had, and there was some discussion on consumer confidence as well. But it was sort of brought up in the sense of, well, what happens when things improve. I hate to be the pessimist here, but can we talk about the other side of things as inflation is one thing and consumer sentiment and consumer confidence is another thing. But recessionary impact, if unemployment goes higher, if job losses start to accelerate, there is a scenario where things are -- should get worse for the next couple of quarters before they get better.
So can you talk through sort of how you view the likelihood of that happening, the impact you think it will have on the business? And also sort of what's your response going to be what's the game plan? You talked a little bit about controlling costs in the quarter already. What would be the other levers you would pull if things for the consumer in the Americas and in Europe get materially worse over the next three to six to nine months?
Joe Hogan
It's Joe. Look, I think you've seen that -- I feel we've been responsible in the sense of adjusting the business to a lower demand signal than the business is used to having. I think you saw us respond the same way when COVID hit in March of in 2020, and how we ran the business. If it gets worse, and it could get worse is the way -- I mean from the standpoint of whatever happens from an economic standpoint.
I'd just say that, look, John and I come from businesses where we've been through these cycles. We know how to operate in a down cycle. We run a business that way. This is a growth business, and we'll treat it as a growth business, but we're responsible from a standpoint of making sure that we adjust this business to whatever economic conditions that we see out there.
John Morici
And as a result, we've been able to make these adjustments. We're fortunate as a company to have the cash position, the balance sheet that we have and all these other. And in the end, you know the story, we have a huge opportunity to be able to grow. You just have this in our way. And like Joe said, and what many others say is it could get worse.
We have to be able to be able to balance those short-term worse to with our long-term goal of being able to make Invisalign the standard of care. And that's what we're balancing right now, and that could play out -- that will play out in the next -- whatever, a year to 18 months, things will evolve. We hope that the economies improve. We hope that that a lot of this has just got a short term and things get better. And when things do get better, we're well positioned to be able to grow into this market, but we just have to be based on the realities of what's happening in short term.
Michael Ryskin
Great. And a quick follow-up, if I can. On 1Q, you kind of gave some comments on pacing through the quarter, and gave some comments on April as it relates to March. Kind of get the sense that things probably slowed down at the end of 2Q or bit in June, both between FX and China lockdowns being worse. Any sense you can give on sort of the progression through the course of 2Q? And just any early signs you've seen from July, again, realize that walk-down in China and FX is playing a big role. But maybe if you could just focus on America's trends through the quarter, and July. That will be helpful.
John Morici
Yes. No, it's a good question. So if you think like an overall picture, you hit some of the FX and so on, you look -- everybody can look at FX rates and see the changes and so on, you can project based on those. When you talk about a COVID lockdown or talk specifically in China, there was an impact for us. And we've seen that in the first quarter, we saw it in the second quarter, but it's -- happens in China. It happens in every place that we see where there's a lockdown, we have a reduction in volume. Where that lockdown goes away, the volume starts to come back. So I would say when you think of China, as you go from lockdown to not lockdown, that's favorable for us. We start to see some of the volume come back.
And I think when you look at -- I think part of your question is around the US, I think what do you see for the US is it's -- maybe things stabilizing a little bit more. You're not seeing -- maybe it's pretty similar to what we exited Q2 into Q3. And I think when you look at the team benefit that ideally comes through with some of the products and programs that we have in teen in the US and other places, but focus on the US, we think that's helpful for us as we go from Q2 to Q3.
Michael Ryskin
Okay. Thanks.
Operator
Thank you, Mr. Ryskin. We have reached the end of our question-and-answer session. I will now turn the call back over to Shirley Stacy for closing remarks.
Shirley Stacy
Thank you, operator, and thank you, everyone, for joining us today. We look forward to speaking to you at upcoming financial conferences and industry meetings. And if you have any follow-up questions, please contact our Investor Relations team. Have a great day.
Operator
Thank you. This concludes today's conference, and you may now disconnect your lines at this time. Thank you for your participation.
- Read more current ALGN analysis and news
- View all earnings call transcripts